Skip to Main Content
Table 1.

Study IMbrave150: baseline demographics and disease characteristics.

Atezolizumab-bevacizumabSorafenib
(N = 336)(N = 165)
Median age, years (range) 64 (26–88) 66 (33–87) 
Male sex, n (%) 277 (82%) 137 (83%) 
Asian country (excluding Japan) 133 (40%) 68 (41%) 
ECOG PS 0/1, n (%) 209 (62%)/127 (38%) 103 (62%)/62 (37%) 
BCLC, n (%) 276 (82%) 133 (81%) 
Hepatitis B/C, n (%) 164 (49%)/72 (21%) 76 (46%)/36 (22%) 
EHS and/or MVI 258 (77%) 120 (73%) 
Child Pugh A5/A6, n (%) 239 (72%)/94 (28%) 121 (73%)/44 (27%) 
AFP ≥ 400 ng/mL 126 (38%) 61 (37%) 
Varices at enrollment 88 (26%) 43 (26%) 
Atezolizumab-bevacizumabSorafenib
(N = 336)(N = 165)
Median age, years (range) 64 (26–88) 66 (33–87) 
Male sex, n (%) 277 (82%) 137 (83%) 
Asian country (excluding Japan) 133 (40%) 68 (41%) 
ECOG PS 0/1, n (%) 209 (62%)/127 (38%) 103 (62%)/62 (37%) 
BCLC, n (%) 276 (82%) 133 (81%) 
Hepatitis B/C, n (%) 164 (49%)/72 (21%) 76 (46%)/36 (22%) 
EHS and/or MVI 258 (77%) 120 (73%) 
Child Pugh A5/A6, n (%) 239 (72%)/94 (28%) 121 (73%)/44 (27%) 
AFP ≥ 400 ng/mL 126 (38%) 61 (37%) 
Varices at enrollment 88 (26%) 43 (26%) 

Abbreviations: AFP, alpha-feto protein; BCLC, Barcelona Clinic Liver Cancer; EHS, extra hepatic disease; MVI, macrovascular invasion.

Close Modal

or Create an Account

Close Modal
Close Modal